University of California San Francisco | About UCSF | UCSF Benioff Children's Hospital San Francisco
Search Site | Find a Doctor

James Rubenstein, Ph.D., M.D.

Blood disorder specialist

Dr. James Rubenstein is a hematologist-oncologist or blood disorders specialist, whose expertise is treating patients with neurologic complications from cancer, in particular patients with non-Hodgkin's lymphoma involving the brain, called central nervous system (CNS) lymphoma. He also specializes in patients with cancer that has spread to the brain from other parts of the body. In his research, he is interested in immunologic tools to improve tumor response to chemotherapy and radiation treatment, to minimize toxicity from treatment and the development of tumor biomarkers to diagnose brain tumors.

Rubenstein earned a medical degree at Cornell University Medical College in New York and completed a residency in internal medicine at Stanford University Medical Center. He earned a Ph.D. in molecular and cellular neurosciences at Rockefeller University in New York and completed a fellowship in hematology and oncology at UCSF, including training in neuro-oncology. He is a member of the American Society of Hematology, American Society of Clinical Oncology and American Association of Cancer Research. He won a Scholar in Clinical Research Award from the Leukemia and Lymphoma Society and a Research Career Award from the National Cancer Institute. He is an associate professor of medicine, in residence.

Clinics

Hematology and Blood and Marrow Transplant
400 Parnassus Ave.,
Suite A-502
San Francisco, CA 94143
Existing Patients: (415) 353-2421
New Patients: (415) 353-2051

Hours: Monday to Friday
8 a.m. – 5 p.m

Conditions & Treatments

More about James Rubenstein

Additional Languages

French

Education

Cornell University Medical College 1992

Residencies

Stanford, Internal Medicine 1995

Fellowships

UCSF Cancer Research Institute, Hematology/Oncology 1997

Selected Research and Publications

  1. Wang CC, Carnevale J, Rubenstein JL. Progress in central nervous system lymphomas. Br J Haematol. 2014 Aug; 166(3):311-25.
  2. Rubenstein JL, Cheson BD, Jung SH, Kaplan LD. Reply to m.C. Chamberlain. J Clin Oncol. 2014 Mar 10; 32(8):858-9.
  3. Kadoch C, Li J, Wong VS, Chen L, Cha S, Munster P, Lowell CA, Shuman MA, Rubenstein JL. Complement activation and intraventricular rituximab distribution in recurrent central nervous system lymphoma. Clin Cancer Res. 2014 Feb 15; 20(4):1029-41.
  4. Rubenstein JL, Gupta NK, Mannis GN, Lamarre AK, Treseler P. How I treat CNS lymphomas. Blood. 2013 Oct 3; 122(14):2318-30.
  5. Rubenstein JL, Wong VS, Kadoch C, Gao HX, Barajas R, Chen L, Josephson SA, Scott B, Douglas V, Maiti M, Kaplan LD, Treseler PA, Cha S, Hwang JH, Cinque P, Cyster JG, Lowell C. CXCL13 plus interleukin 10 is highly specific for the diagnosis of CNS lymphoma. Blood. 2013 Jun 6; 121(23):4740-8.
  6. Rubenstein JL, Hsi ED, Johnson JL, Jung SH, Nakashima MO, Grant B, Cheson BD, Kaplan LD. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). J Clin Oncol. 2013 Sep 1; 31(25):3061-8.
  7. Scott BJ, Douglas VC, Tihan T, Rubenstein JL, Josephson SA. A systematic approach to the diagnosis of suspected central nervous system lymphoma. JAMA Neurol. 2013 Mar 1; 70(3):311-9.
  8. Rubenstein JL, Li J, Chen L, Advani R, Drappatz J, Gerstner E, Batchelor T, Krouwer H, Hwang J, Auerback G, Kadoch C, Lowell C, Munster P, Cha S, Shuman MA, Damon LE. Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma. Blood. 2013 Jan 31; 121(5):745-51.
  9. Wieduwilt MJ, Valles F, Issa S, Behler CM, Hwang J, McDermott M, Treseler P, O'Brien J, Shuman MA, Cha S, Damon LE, Rubenstein JL. Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI. Clin Cancer Res. 2012 Feb 15; 18(4):1146-55.
  10. Chan CC, Rubenstein JL, Coupland SE, Davis JL, Harbour JW, Johnston PB, Cassoux N, Touitou V, Smith JR, Batchelor TT, Pulido JS. Primary vitreoretinal lymphoma: a report from an International Primary Central Nervous System Lymphoma Collaborative Group symposium. Oncologist. 2011; 16(11):1589-99.
  11. Rubenstein JL, Treseler PA, Stewart PJ. Regression of refractory intraocular large B-cell lymphoma with lenalidomide monotherapy. J Clin Oncol. 2011 Jul 10; 29(20):e595-7.
  12. Algazi AP, Kadoch C, Rubenstein JL. Biology and treatment of primary central nervous system lymphoma. Neurotherapeutics. 2009 Jul; 6(3):587-97.
  13. Kadoch C, Dinca EB, Voicu R, Chen L, Nguyen D, Parikh S, Karrim J, Shuman MA, Lowell CA, Treseler PA, James CD, Rubenstein JL. Pathologic correlates of primary central nervous system lymphoma defined in an orthotopic xenograft model. Clin Cancer Res. 2009 Mar 15; 15(6):1989-97.
  14. Mrugala MM, Rubenstein JL, Ponzoni M, Batchelor TT. Insights into the biology of primary central nervous system lymphoma. Curr Oncol Rep. 2009 Jan; 11(1):73-80.
  15. Rubenstein JL, Shen A, Batchelor TT, Kadoch C, Treseler P, Shuman MA. Differential gene expression in central nervous system lymphoma. Blood. 2009 Jan 1; 113(1):266-7; author reply 267-8.
  16. Yang I, Delpolyi A, Sughrue ME, Rubenstein J, Bollen AW, Parsa AT. Sarcoidosis of the pineal gland: an unusual presentation of neurosarcoidosis. J Neurooncol. 2009 Jan; 91(1):113-6.
  17. Rubenstein J, Ferreri AJ, Pittaluga S. Primary lymphoma of the central nervous system: epidemiology, pathology and current approaches to diagnosis, prognosis and treatment. Leuk Lymphoma. 2008; 49 Suppl 1:43-51.
  18. Roy S, Josephson SA, Fridlyand J, Karch J, Kadoch C, Karrim J, Damon L, Treseler P, Kunwar S, Shuman MA, Jones T, Becker CH, Schulman H, Rubenstein JL. Protein biomarker identification in the CSF of patients with CNS lymphoma. J Clin Oncol. 2008 Jan 1; 26(1):96-105.
  19. Rubenstein JL, Fridlyand J, Abrey L, Shen A, Karch J, Wang E, Issa S, Damon L, Prados M, McDermott M, O'Brien J, Haqq C, Shuman M. Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol. 2007 Apr 10; 25(11):1350-6.
  20. Kadoch C, Treseler P, Rubenstein JL. Molecular pathogenesis of primary central nervous system lymphoma. Neurosurg Focus. 2006; 21(5):E1.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.